Results 1 to 10 of about 789 (118)

Boron‐10 carriers and their applications in boron neutron capture therapy [PDF]

Precision Radiation Oncology
Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
doaj   +3 more sources

PK Modeling of L-4-Boronophenylalanine and Development of Bayesian Predictive Platform for L-4-Boronophenylalanine PKs for Boron Neutron Capture Therapy [PDF]

Pharmaceuticals
L-4-[(10B)]Boronophenylalanine (BPA) is an amino acid analogue with a boron-10 moiety. It is most widely used as a boron carrier in boron neutron capture therapy.
Woo Hyoung Kim, Hyeong-Seok Lim
exaly   +4 more sources

Safety, efficacy, pharmacokinetics, and mechanisms of novel ¹⁰B-boronophenylalanine combined with a radio-frequency quadrupole accelerator in boron neutron capture therapy: A preclinical study in head and neck squamous cell carcinoma. [PDF]

Precis Radiat Oncol
This study demonstrates that the novel 10B‐BPA‐based BNCT system, combined with an RFQ accelerator, effectively targets head and neck squamous cell carcinoma. It induces tumor regression safely and efficiently by triggering DNA damage and activating the ROS/HIF‐1α/NF‐κB pathway, leading to caspase‐3‐mediated apoptosis.
Zhang Z, Li J, Fan M, Ouyang H, Chu Q, Yan H, Zheng Y, Huang L, Bao G, Ma Z, Huang S, Li L, Xu X, Liu Z.   +13 more
europepmc   +2 more sources

Automated radiosynthesis of 2-[18F]BPA for PET-based planning of boron neutron capture therapy (BNCT): rational precursor design, radiofluorination, and characterization of methodology [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Boron neutron capture therapy relies on the selective accumulation of boron-containing compounds in tumor tissue, making accurate quantification of boron distribution essential for effective treatment planning.
Vincenzo Paolillo, Cong-Dat Pham, Robert Ta, Dimitra K. Georgiou, Henry Charles Manning   +4 more
doaj   +2 more sources

Transporter-Associated Therapeutic Efficacy of an SMVT-Targeted Boron Carrier in Boron Neutron Capture Therapy. [PDF]

Cancer Sci
The transporter‐associated BNCT strategy using BBCIP with or without BPA according to tumor transporter characteristics. BPA showed greater efficacy in LAT1‐dominant F98 glioma, whereas BBCIP was more effective in SMVT‐high CRL1666 tumors, suggesting the potential utility of transporter‐based boron carrier selection in BNCT.
Eza K, Tsujino K, Shidoh-Kazuki R, Fujikawa Y, Kashiwagi H, Futamura G, Hiramatsu R, Takami T, Wanibuchi M, Hu N, Tanaka H, Suzuki M, Nishimura K, Tanaka S, Nakamura H, Kawabata S.   +15 more
europepmc   +2 more sources

Sensitization for proton beam therapy using 10B enriched and natural isotopic abundance of boronophenylalanine [PDF]

Scientific Reports
Nuclear reactions between proton irradiation and boron via p + 11B→3α (boron proton-capture reaction; BPCR) and n + 10B→α+7Li (boron neutron-capture reaction; BNCR) enhance the cell-killing effects of proton beam irradiation (PBI); however, which ...
Shintaro Shiba, Takahiro Shimo, Masashi Yamanaka, Makoto Sakai, Tatsuya Ohno, Koichi Tokuuye, Motoko Omura   +6 more
doaj   +2 more sources

Boron Neutron Capture Therapy as a Novel Approach for Chondrosarcoma: Case Study of Tumor Reduction and Long-term Control [PDF]

Advances in Radiation Oncology
Purpose: Mesenchymal chondrosarcoma (MCS), a rare malignant tumor arising from cartilage-forming tissues, is known for its resistance to conventional therapies.
Junqiang Hong, MD, Yuan-Hao Liu, PhD, Xiaohua Zhu, MD, PhD, Yi-Chiao Teng, PhD, Xiaoyi Lin, MD, Diyun Shu, PhD, Youqun Lai, MS, Ye Cao, PhD, Qiuping Gong, BEng, Shuang Fu, BS, Wenyu Xu, MS, Qiuli Lai, BS, Xingyan Liu, PhD, Ping Zhou, PhD, Mu Mei, MS, Mingang Ying, MD, PhD, Cheng Huang, MD, PhD, Jianji Pan, MD, PhD   +17 more
doaj   +2 more sources

The Therapeutic Effects of Dodecaborate Containing Boronophenylalanine for Boron Neutron Capture Therapy in a Rat Brain Tumor Model

Biology, 2020
Background: The development of effective boron compounds is a major area of research in the study of boron neutron capture therapy (BNCT). We created a novel boron compound, boronophenylalanine–amide alkyl dodecaborate (BADB), for application in BNCT and
Shinji Kawabata, Takuya Kanemitsu, Shin-Ichi Miyatake   +2 more
exaly   +3 more sources

Emerging agents for boron neutron capture therapy: Biomolecular carriers paving the way for precision radiotherapy. [PDF]

Precis Radiat Oncol
Boron neutron capture therapy (BNCT) requires key non‐negotiable technical criteria: megadose administration, precise tumor‐specific targeting, favorable biocompatibility, and sustained tumor retention. Overcoming these interconnected challenges fundamentally depends on biomolecular carriers, which are critical for translating the therapeutic potential
Chen C, Yang M, Wang J, Zhang L, Huang S, Xu X, Liu Y.   +6 more
europepmc   +2 more sources

Comparison of the Biological Response of a Head and Neck Carcinoma and a Glioblastoma Cell Line Under Neutron Irradiation with BPA Administration [PDF]

Biology
Background and objective: In Boron Neutron Capture Therapy, treatment planning is based on a weighted dose in which dose components are weighted with different biological effectiveness (RBE) factors.
Patricia Álvarez-Rodríguez, Cristina Méndez-Malagón, Maribel Porras-Quesada, María Pedrosa-Rivera, Ulli Köster, Ignacio Porras, Javier Praena, Rocío Estrada, Leonor Pérez-Fuentes, Juan Luis Osorio-Ceballos, Carmen Ruiz-Ruiz, Lucie Sancey, María José Ruiz-Magaña   +12 more
doaj   +2 more sources